DHR Stock Recent News
DHR LATEST HEADLINES
DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.
Danaher Corporation (NYSE:DHR ) Q1 2025 Earnings Conference Call April 22, 2025 8:00 AM ET Company Participants John Bedford - VP, IR Rainer Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Michael Ryskin - Bank of America Tycho Peterson - Jefferies Scott Davis - Melius Research Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Rachel Vatnsdal - JPMorgan Daniel Brennan - TD Cowen Daniel Arias - Stifel Operator My name is Chelsy, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's First Quarter 2025 Earnings Results Conference Call.
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher Corp DHR on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the consensus of $5.59 billion.
Danaher (DHR) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.92 per share a year ago.
WASHINGTON , April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.
DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.
Besides Wall Street's top -and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Citi added Danaher to the firm's Focus List while keeping a Buy rating on the shares with a $265 price target. The firm sees an attractive opportunity to step into the name, saying the bioprocessing recovery continues to materialize 22 Apr 06 May